{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:32:25Z","timestamp":1787164345091,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile of lorlatinib based on the Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reports from the FAERS between 2019 and 2023 were collected to conduct the disproportionality analysis. Reporting odds ratio (ROR) was employed to detect the potential adverse events (AEs) related to lorlatinib. The clinical characteristics, age and gender differences, time to onset of AEs were also investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,941 AE reports were found to be associated with lorlatinib among the 8,818,870 AE reports obtained from the FAERS database. 167 lorlatinib-related AE signals were identified. The frequently reported AEs including hypercholesterolemia, oedema, and cognitive disorder were in line with those observed in clinical trials and drug instruction. However, AEs such as interstitial lung disease and AV block indicated in the drug label require further evaluation. More attention should be paid to the new potential unexpected AEs including pulmonary arterial hypertension and radiation necrosis. Furthermore, we examined the specific high-risk AEs of different ages and genders. In addition, majority of AEs occurred within the first 2\u00a0months after lorlatinib initiation with a median onset time of 51\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study provides valuable insight into the post-marketing safety profile of lorlatinib, which can potentially benefit the rational and safe administration of lorlatinib in the clinic. Further prospective studies are needed to validate the associations between lorlatinib and the identified AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1385036","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:34:37Z","timestamp":1717547677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Huqun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.3390\/cancers13153704","article-title":"Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in asian and non-asian patients: a systematic review and network meta-analysis","volume":"13","author":"Ando","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2018.03.023","article-title":"Lorlatinib - induced pulmonary arterial hypertension","volume":"120","author":"Chabrol","year":"2018","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/cpt.2228","article-title":"Lorlatinib exposure-response analyses for safety and efficacy in a phase I\/II trial to support benefit-risk assessment in non-small cell lung cancer","volume":"110","author":"Chen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000520158","article-title":"An unusual case of lorlatinib-induced pneumonitis: a case report","volume":"15","author":"Harrison","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.idc.2017.07.015","article-title":"Bacterial pneumonia in older adults","volume":"31","author":"Henig","year":"2017","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13256-022-03556-8","article-title":"Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report","volume":"16","author":"Kashizaki","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"858279","DOI":"10.3389\/fphar.2022.858279","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2169\/internalmedicine.55.5076","article-title":"Promising effect of crizotinib on anaplastic lymphoma kinase (ALK)-Positive non-small cell lung cancer in an elderly patient with a poor performance status: a case report and literature review","volume":"55","author":"Matsuo","year":"2016","journal-title":"Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ijrobp.2016.08.039","article-title":"Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis","volume":"96","author":"Miller","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14740\/wjon1092w","article-title":"A case series of two patients presenting with pericardial effusion as first manifestation of non-small cell lung cancer with BRAF mutation and expression of PD-L1","volume":"9","author":"Mufti","year":"2018","journal-title":"World J. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tlcr-20-564","article-title":"Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series","volume":"10","author":"Myall","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2016.03.008","article-title":"Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation","volume":"96","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/jco.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/s1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.arbres.2018.01.030","article-title":"Factors affecting lung function: a review of the literature","volume":"54","author":"Talaminos Barroso","year":"2018","journal-title":"Arch. Bronconeumol Engl Ed."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.jgo.2023.101636","article-title":"Representation of older patients in the safety analysis of protein kinase inhibitor registration studies","volume":"14","author":"van Kampen","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fonc.2018.00395","article-title":"Diagnosis and management of radiation necrosis in patients with brain metastases","volume":"8","author":"Vellayappan","year":"2018","journal-title":"Front. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1378\/chest.118.3.744","article-title":"Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer","volume":"118","author":"Wang","year":"2000","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17512433.2019.1570846","article-title":"Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/14740338.2023.2245324","article-title":"Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study","volume":"22","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/lctt.S224991","article-title":"Symptomatic CNS radiation necrosis requiring neurosurgical resection during treatment with lorlatinib in ALK-rearranged NSCLC: a report of two cases","volume":"11","author":"Zhu","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T06:00:25Z","timestamp":1721368825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1385036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1385036"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1385036","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"article-number":"1385036"}}